Precision BioSciences, Inc. has reported its financial results for the third quarter of 2026, emphasizing significant progress in its clinical trials. The company, which specializes in gene editing therapies, is making strides in addressing chronic hepatitis B and Duchenne muscular dystrophy (DMD). This update is crucial as it showcases the company's commitment to delivering innovative treatments for high unmet medical needs.

Background

Precision BioSciences, Inc. operates in the biological products sector (SIC: 2836) and is listed on the Nasdaq under the ticker DTIL. The company is dedicated to developing in vivo gene editing therapies using its proprietary ARCUS platform. Recent filings include an 8-K on November 3, 2026, and a 10-Q on the same date, both detailing its financial performance and business updates.

What the Filing Says

According to the filing, "On November 3, 2026, Precision BioSciences, Inc. issued a press release announcing its financial results and provided a business update for the quarter ended September 30, 2026." The press release, which is included as Exhibit 99.1, outlines the company's advancements and financial standing.

Impact

This update may significantly affect stakeholders, including investors, healthcare providers, and patients relying on innovative treatments for chronic diseases. The company's progress in clinical trials could lead to new treatment options, particularly for those suffering from hepatitis B and DMD.

What's Next

The filing does not say what happens next, but the company is expected to continue its clinical trials and provide further updates as they progress. Notably, Precision BioSciences will present important clinical data at the upcoming AASLD Liver Meeting on November 8, 2026.